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Abstract
Prostate cancer is an age-associated epithelial cancer, and as such, it contributes significantly to the mortality of
the elderly. Senescence is one possible mechanism by which the body defends itself against various epithelial
cancers. Senescent cells alter the microenvironment, in part, through changes to the extracellular matrix. Laminins
(LMs) are extracellular proteins important to both the structure and function of the microenvironment. Overex-
pression of the senescence-associated gene mac25 in human prostate cancer cells resulted in increased mRNA
levels of the LM α4 and β2 chains compared to empty vector control cells. The purpose of this study was to ex-
amine the effects of these senescence-induced LM chains on tumorigenicity of prostate cancer cells. We created
stable M12 human prostate cancer lines overexpressing either the LM α4 or β2 chain or both chains. Increased
expression of either the LM α4 or β2 chain resulted in increased in vitro migration and in vivo tumorigenicity of
those cells, whereas high expression of both chains led to decreased in vitro proliferation and in vivo tumori-
genicity compared to M12 control cells. This study demonstrates that senescent prostate epithelial cells can alter
the microenvironment and that these changes modulate progression of prostate cancer.
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Introduction
Prostate cancer is the most common cancer and the second leading
cause of illness and death for men older than 50 years in western
countries [1,2]. Possible mechanisms for defense against epithelial
cancers, such as prostate, include promotion of apoptosis in which
the damaged cell dies or senescence in which the cell ceases to divide
but remains metabolically active. An accumulation of mutations,
which is believed to occur during the life span of an organism, is
not sufficient to cause cancer [3]; instead, these initiated premalig-
nant cells require a permissive microenvironment in which to prog-
ress [4,5]. The accrual of senescent cells as an organism ages may
provide such an environment owing to secreted factors that com-
promise tissue structure and function. Studies examining the effects
of senescent fibroblasts on the growth of premalignant epithelial
cells demonstrated increased growth and tumorigenicity of those epi-
thelial cells [6,7]. Senescence then acts to inhibit cancer formation in
a younger organism, but over time, the accumulation of senescent
cells alters the microenvironment to one that can promote the
growth of epithelial cancers [5–8].
Abbreviations: LM, laminin; LM332, laminin α3β3γ2; LM411, laminin α4β1γ1;
LM421, laminin α4β2γ1; LM511, laminin α5β1γ1; LNCaP, human prostate cancer
cell line derived from a lymph-node metastasis; mac25, senescence-associated gene also
known as IGFBP-7/IGFBP-rP1/TAF; M12, human prostate cancer cell line derived
from SV-40T–immortalized benign prostate epithelial cells; MECA, mouse endothe-
lial cell antigen; PEC, primary prostate epithelial cells
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Although senescence of fibroblasts has been studied heavily, a paucity
of studies on the senescence of epithelial cells has been completed [9–
14]. After 30 doublings, cultured primary prostatic epithelial cells stain
positive for senescence-associated (SA)-β-galactosidase [9] and exhibit
increased protein levels of p16 and mac25 (IGFBP-7/IGFBP-rP1)
[10–12]. Staining for SA-β-gal in various prostate tissues demonstrated
the presence of senescent epithelial cells primarily in regions of benign
prostatic hyperplasia and prostatic intraepithelial neoplasia but rarely in
cancer [9,15]. However, reports of chemotherapeutic agents inducing
a senescence-like state in cancer cells, including prostate cancer cells,
imply that cancer cells are capable of undergoing senescence as well
[16–18]. We have demonstrated that transfection of the senescence-
associated genemac25 into theM12 and LNCaP human prostate cancer
cell lines resulted in increased senescence, decreased proliferation, a de-
lay in G1, and decreased in vitro and in vivo tumorigenicity [19–21].
Senescent fibroblasts modify the microenvironment [7], but the oc-
currence of such alterations by senescent cancer cells has not been
examined previously. Using cDNA microarrays, we found that senes-
cent M12 and LNCaP prostate cancer cells have increased transcript
levels of the laminin (LM) α4 and β2 chains, among other genes (un-
published data). Laminins are a major constituent of the extracellular
matrix that link the ECM to cells through various cell surface recep-
tors [22]. They are large, heterotrimeric, cruciform matrix glycopro-
teins composed of highly homologous α, β, and γ chains; specific
LM isoform expression and posttranslational processing can directly
influence cellular response to growth factors, intracellular signaling,
cell proliferation, susceptibility to apoptosis, and migratory capacity
[23]. In various cancers, including breast cancer, increased expression
of the LM α4 and β1 chains is associated with increased tumori-
genicity and angiogenesis [22,24,25]. In prostate cancer, changes in
LM composition within the prostate tumor microenvironment have
been associated with the progression of cancer [26]. Studies specifically
examining alterations in LM expression during senescence have not
been undertaken.
The purpose of this study was to examine the effects of senescence-
induced LM chains on the tumorigenicity of prostate cancer cells. We
created stable M12 prostate cancer cell lines overexpressing either
the LM α4 or β2 chains or both the LM α4 and β2 chains. We
demonstrate that overexpression of either the LM α4 or β2 chains in-
creased tumorigenicity of prostate cancer cells, whereas overexpression
of both chains decreased tumorigenicity. Our investigation of the ef-
fects of senescence on behavior of cancer cells will provide insight into
how current prostate cancer therapies influence cancer progression.
Methods
Reagents
Tissue culture media, additives, and antibiotics were purchased
from GIBCO (Grand Island, NY). SYBR GREEN PCR Master
Mix was from Applied Biosystems (Foster City, CA). The BCA pro-
tein assay kit was from Pierce Biological (Rockford, IL). Nitrocel-
lulose and polyacrylamide gel electrophoresis (PAGE) reagents were
purchased from BioRad Laboratories (Richmond, CA). Laminin
antibodies used in Western immunoblot analyses were obtained
from Santa Cruz Biologicals (Santa Cruz, CA), whereas LM and fi-
bronectin antibodies used for immunofluorescent staining were pro-
duced at Fred Hutchinson Cancer Research Center (Seattle, WA).
Fluorescent-conjugated secondary antibodies were purchased from
Invitrogen (Hercules, CA). Horseradish peroxidase–linked anti–rabbit
secondary antibody and enhanced chemiluminescence reagents were
purchased from Amersham Pharmacia Biotech (Piscataway, NJ). Re-
striction enzymes were obtained from Promega (Madison, WI). The
pcDNA3.1 expression vector was purchased from Invitrogen.
Cell Culture
Primary prostate epithelial cells (PECs) were obtained from Dr.
Beatrice Knudsen (Fred Hutchinson Cancer Research Center, Seattle,
WA) and grown with keratinocyte growth medium supplemented
with epidermal growth factor and bovine pituitary extract. The deri-
vation of the M12 cell line has been previously described [27]. M12
and M12-LM cells were cultured in RPMI 1640 supplemented with
10 ng/ml epidermal growth factor, 0.1 mM dexamethasone, 5 μg/ml
insulin, 5 μg/ml transferrin, 5 ng/ml selenium, fungizone, 50 μg/ml
gentamicin, and 5% fetal calf serum at 37°C under 5%CO2. All of the
cells used in these experiments were mycoplasma-free, as determined
by the PCRMycoplasmTest Kit (MDBiosciences, Zurich, Switzerland).
Vector Preparation
The mammalian expression vector pcDNA3.1 (Invitrogen) was
used to prepare the LMα4 and β2 chain constructs, which expressed
the LM cDNA from the constitutively active cytomegalovirus pro-
moter. The 6.5-kb full-length LMα4 chain (LAMA4) cDNA was ob-
tained from OriGene (Rockville, MD) in their nonselectable vector
(pCMV6-XL4). We subcloned the LAMA4 cDNA as an EcoRI/
HindIII fragment into pcDNA3.1Neo. The LMβ2 chain (LAMB2)
cDNA was generated by polymerase chain reaction (PCR) with Pfu
DNA polymerase (Promega) using the following primers:
LAMB2
forward: AGACCGTTCACCTCCCCTTATC
reverse: TTCAGTGCATAGGCAGACATGC
A 5.6-kb cDNA fragment containing the full-length coding se-
quence was ligated into the pcDNA3.1Hygro EcoRV site. Orientation
of cDNA was determined by restriction digestion.
Transfection
Cell lines overexpressing the LMα4, β2, or both the α4 and β2
chains were produced by liposome-mediated transfection of the M12
human prostate cancer cell line using pFx-5 (Invitrogen) according
to the manufacturer’s instructions. Transfecting the M12 cells with
pcDNA3.1 alone produced control cells. M12α4β2 cells were created
sequentially, first by transfection and selection for LMα4 (800 μg/ml
G418), then by transfection with the LAMB2 cDNA and selection
for LMα4 (800 μg/ml G418) and LMβ2 (100 μg/ml hygromicin).
Surviving transfected cells were maintained with either 400 μg/ml
G418 (M12α4 cells), 400 μg/ml G418 plus 50 μg/ml hygromicin
(M12α4β2 cells), or 50 μg/ml hygromicin (M12β2 cells). Total cell
lysates and RNA were isolated and analyzed for expression of var-
ious LM chains, including the LMα4 and β2 chains (see the Western
Immunoblot Analysis, Immunofluorescent Staining, and Real-time
PCR subsections).
Real-time PCR
Total RNAwas obtained frommonolayer cell cultures using Qiagen
RNeasy Plus (Valencia, CA); the optional on-column DNase di-
gestion was used. RNA was converted to cDNA using SuperScript
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First-Strand Synthesis System according to themanufacturer’s protocol
with random primers (Invitrogen). Relative real-time PCR was then
performed using an ABI 7900HT sequence detection system using
SYBR GREEN PCR master mix (Applied Biosystems) as follows:
stage 1: 50°C for 2 minutes; 95°C for 10 minutes; stage 2 (40-45 cy-
cles): 95°C for 15 seconds; 60°C for 1 minute; 72°C at 20 seconds;
stage 3 (dissociation curve): 95°C for 15 seconds; 60°C for 15 seconds;
95°C for 15 seconds. Polymerase chain reaction data were analyzed
using Primer Express Software v2.0 (Applied Biosystems). Target
mRNA levels were normalized against glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) levels. The following primer pairs were used:
LAMA3
forward: GACACCAATCTCACAACTCTCCG
reverse: ATGGGGACAGCAACCTTACTGG
LAMA4
forward: GCCGCTTGGTTTACATGTTT
reverse: AATGGGACCCTTGATTTTCC
LAMB1
forward: AAGGATTCCAACCAGCAGCC
reverse: TCATCGGTGTTTTCACAACGC
LAMB2
forward: CCCTGAGCCTGACAGACATAAATG
reverse: TGCTGAGGATGCTACCACCTTC
LAMB3
forward: TCAGAGGAAGAGGGAGCAGTTTG
reverse: GGTCAGGCAACGAAGACATCTC
LAMC1
forward: GAATCATCTAATCCTCGGGGTTG
reverse: TCAAGCACAAGGTCTTCGGCAG
LAMC2
forward: CAGGAGATTGTTATTCAGGGG
reverse: TGGGGTCCACATTGTTGTTGC
GAPDH
forward: GAAGGTGAAGGTCGGAGTC
reverse: GAAGATGGTGATGGGATTTC
Western Immunoblot Analysis
Total cell lysates were prepared by addition of cold lysis buffer
(30 mM HEPES, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA,
10% Triton X-100) containing protease and phosphatase inhibitors
(Protease and Phosphatase Inhibitor Cocktail II; Sigma, St. Louis, MO)
to monolayer cultures. Conditioned medium was concentrated using
Centricon YM-10 columns (Millipore, Billerica, MA). For both lysates
and media, total protein concentration was determined with the BCA
protein assay kit (Pierce Biological). Reducing sample buffer (Pierce Bio-
logical) was added to 25 μg of each sample. Samples were boiled for
5 minutes before running on 5% SDS–PAGE gels. Proteins were then
transferred to nitrocellulose in buffer containing 15 mM Tris base,
120 mM glycine, and 5% methanol. Membranes were blocked with
Tris-buffered saline (TBS is 20 mM Tris-HCl, pH 7.5, containing
0.15 M NaCl) plus 5% nonfat milk. Blots were incubated overnight
at 4°C with appropriate antibodies in TBS/0.1% Tween 20/5% non-
fat milk. Tris-buffered saline/0.3% Tween 20 was used for all washes.
Blots were incubated for 1 hour at room temperature in horseradish
peroxidase–linked secondary antibodies, diluted in TBS/0.1% Tween
20/ 5% nonfat milk. Bands were detected using enhanced chemilumines-
cence reagents (ECL system) according to the manufacturer’s protocol.
Immunoprecipitation
Serum-free medium was collected from cells after 24 hours. Five
hundred microliters of medium was precleared with 1 μg of appro-
priate control IgG plus 20 μl of Protein A/G agarose beads (Pierce
Biological) for 30 minutes at 4°C. The supernatant was transferred to
a new tube and brought up to 1 ml with RPMI T&S. We added 2 μg
of either LMα3 or LMγ2 chain antibody to each sample and incu-
bated on a rotating carousel overnight at 4°C. After incubation, we
washed the beads three times with 1× PBS and resuspended them in
Laemmli sample buffer with β-mercaptoethanol. Samples were
boiled for 5 minutes and then loaded onto 5% SDS-PAGE gels
(see Western Immunoblot Analysis subsection).
Immunofluorescent Staining
Cells were plated onto sterile round microscope slides in 24-well
plates and grown to 70% confluence. After washing with PBS, cells
were fixed with a cold methanol/acetone mixture (1:1) for 1 minute,
followed by two washes with PBS. Cells were blocked with heat-
denatured BSA (0.2%) for 1 hour at room temperature. Primary anti-
bodies [LMα4 (H-194), LMβ2 (H-300), LMα3 (D2-1 or C2-5),
LMβ3 (A2′-2), LMγ2 (B46), LMβ1γ1 (R5922), and fibronec-
tin (R790)] were diluted in heat-denatured BSA and incubated at
room temperature for up to 3 hours. After PBS washes, fluorescent-
conjugated secondary antibodies (anti–rat 488, anti–mouse 488, and
anti–rabbit 568) were added for 30 minutes at room temperature. After
PBSwashes, cells were fixed againwith 2% formaldehyde for 10minutes
at room temperature. Cells were viewed and images acquired using
a Zeiss fluorescence microscope with a Photometric SenSys cooled
CCD digital camera (Roper Industries, Trenton, NJ). Images were
analyzed with MetaMorph (Universal Imaging, Downington, PA) and
ImageJ (rsbweb.nih.gov/ij/) software.
Cell Proliferation Assays
The rate of cellular proliferation in culture was measured by a col-
orimetric MTS assay, using the Cell Titer 96 AQueous kit from Pro-
mega. M12pc, M12α4, M12β2, M12α4β2, and M12mac25 cells
were seeded in 96-well plates at 5000 cells per well in complete
RPMI medium. Twenty-four hours later, medium was switched to
RPMI minus growth factors and serum. After adding the tetrazolium
salt/dye solution for the MTS assays, plates were incubated at 37°C
for 2 hours. One 96-well plate was read per day for 5 days. Quantita-
tion was accomplished by reading absorbance at 490 nm; day 1 mea-
surements were used as a baseline. To validate MTS results by direct
measurement of cell number, cells were plated in 24-well plates
(104 cells per well) and grown for 96 hours as in the MTS assay; cell
counts were performed every 24 hours using a hemocytometer, again
with day 1 used as a baseline (data not shown). Both assays were re-
peated six times; results shown are the average of the six experiments.
Wounding Assays
Wounding assays were used to assess migration of the cells.
M12pc, M12α4, M12β2, M12α4β2, and M12mac25 cells were
plated in six-well plates with complete RPMI medium and grown
to confluence. After rinsing the cells twice with PBS, the cell layer
was scratched with a 10-μl pipette tip, and RPMI T&S medium
was added. Wound width was measured at 0, 1, 3, 6, 9, 12, and
24 hours after wounding. Nine hours after wounding yielded the
most significant differences in wound closure among the cell lines.
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Wounding assays were repeated three separate times; results shown
are the average of the three experiments.
Tumor Formation In Vivo
Groups of 10 nude athymic male mice were injected subcutane-
ously with M12pc, M12α4, M12β2, M12α4β2, or M12mac25 cells
(106 cells per mouse). Mice were maintained on a laboratory diet
ad libitum and were monitored weekly for tumor formation and
weight gain/loss for a duration of 6 weeks. If tumors were present,
tumor volume was calculated using the formula: (l × w2)/2, where l is
length and w is width of tumor. For comparing final tumor volumes
at 6 weeks, statistical analyses using analysis of variance followed by
Fisher's protected least significant difference (Fisher's PLSD) were
performed. After 6 weeks, the mice were euthanized, and their tumors
were removed and measured.
Tumor Analyses
Tumors were divided into thirds and treated as follows: (1) fixed
in formalin, 1 hour, (2) frozen in optimal cutting temperature (OCT),
or (3) digested with 0.1% collagenase (type I) and 50 μg/ml DNase
(Worthington Biochemical Corp., Lakewood, NJ). Digested tumor
cells were plated in RPMI complete medium plus selective antibiotics
at 5% CO2, 37°C. Cell lysates, media, and RNA were prepared and
analyzed by Western blot analysis or real-time PCR to confirm re-
tention of LM expression. Fixed and frozen tumor sections were sliced
(5 μm thick for formalin-fixed and 10 μm thick for frozen) on a cryostat
and mounted on slides for immunohistochemistry. The presence of tu-
mor vasculature was assessed on frozen tissue using a rat anti–mouse
endothelial cell antigen (MECA; Developmental Studies Hybridoma
Bank, University of Iowa, Iowa City, IA). We used Masson’s Trichrome
staining on paraffin-embedded tumors to assess the amount of ECM,
specifically collagen, present.
Results
Altered Expression of LM Chains in Senescent
Prostate Cancer Cells
As mentioned earlier, senescent M12 and LNCaP prostate cancer
cells had increased LMα4 and β2 chain transcripts on cDNA micro-
arrays. To confirm increased expression in the senescent M12mac25
prostate cancer cell line, we used real-time PCR andWestern immuno-
blot analysis. mRNA and protein levels of the LMα4 and β2 chains
were increased in the M12mac25 cells compared to the M12 empty
vector (M12pc) cells (Figure 1, A and B). Because LM332 (α3β3γ2,
formerly LM-5) is the predominant LM in prostate, we evaluated the
levels of the component chains of LM332 in the M12 prostate cancer
lines and compared them to levels found in PECs. We found that
mRNA and protein levels of all three chains (α3, β3, and γ2) were de-
creased in both the nonsenescent M12pc and senescent M12mac25
cells compared to the PECs (Figure 1, A and B), mirroring the decrease
in LM332 that has been reported to occur in vivo during prostate cancer
progression [28].
Construction of M12 LM α4, β2, and α4β2
Chain-Overexpressing Cells
To examine the role of senescence-induced LM chain expression in
prostate cancer tumorigenesis, we created M12 prostate cancer cell
lines stably overexpressing the LM α4 or β2 chains or both the α4
and β2 chains. Transfections were repeated three to four times with
each construct to ensure consistency of characteristics. All of the
transfected cells stably overexpressed both mRNA (Figure 2A) and
protein (Figure 2B) of the selected LM chains. Like M12pc cells,
high-expressing M12α4 populations were cuboidal (Figure 3),
whereas the high-expressing M12β2 and M12α4β2 populations were
a mix of cuboidal and elongated cells (Figure 3). The appearance of
cell populations with an elongated morphology was intriguing be-
cause we have previously shown that M12 cells overexpressing the
senescence-associated gene mac25 or the chondrogenesis-associated
transcription factor SOX9 (which is up-regulated on arrays of senes-
cent epithelial cells) [21,29] also displayed an elongated morphology
and overexpressed both the LMα4 and β2 chain mRNA and protein
[19,20,30].
Immunofluorescent Staining
Whereas immunofluorescent staining for various LM chains demon-
strated patterns similar to those found in the Westerns, it also provided
the opportunity to determine whether the cells deposited the various
LM chains into the ECM. Sigle et al. [31] demonstrated that cell lines
Figure 1. mRNA and protein levels for the various LM chains in
prostate cells. (A) Real-time PCR for LM chains. RNA from PEC,
M12 prostate cancer cells, and M12mac25 cells was converted
to cDNA then amplified using primers for the various LM chains.
No significant differences among cell lines were detected for the
LMβ1 or γ1 chains. *P < .005, **P < .001, ***P < .0001 com-
pared to M12 levels. (B) Western immunoblots against various
LM chains. Whole cell lysates, which include cytoplasmic and
ECM-deposited LM chains, were run on reducing SDS-PAGE gels,
transferred to nitrocellulose, and blotted with antibodies against
various LM chains. No differences in protein expression were seen
for the LMβ1 and γ1 chains.
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do not necessarily deposit the LMs they secrete; thus, it was important to
determine which LM chains were being incorporated into the ECM.
LM332 is classically laid down in a monolayer, which in vitro is de-
scribed as exhibiting a rose petal pattern. Staining for the three LM
chains found in LM332 showed some deposition of LM332 in
a monolayer for the M12pc and M12 LM cells but not for the
M12mac25 cells (Figure 4B). In addition, the M12α4β2 cells, and to
a lesser degree the M12β2 cells, displayed a three-dimensional fibrillar
staining pattern for the three chains comprising LM322 (Figure 4B).
Staining for the LMβ2 chain demonstrated primarily cytoplasmic
staining in the LMβ2-overexpressing cells (M12β2, M12α4β2, and
M12mac25 cells), with occasional fibrillar staining (Figure 4, A and B).
When the cells were removed before staining, faint staining for the
LMβ2 chain could be detected in the ECM from LMβ2-overexpressing
cells but not in ECM from M12pc or M12α4 cells (Figure 4B). We
were not able to successfully use the commercial LMα4 chain antibody
for staining of cells; however, when we removed the cells before stain-
ing the matrix, we detected faint staining of the LMα4 chain in the
M12α4β2 and M12mac25 matrices (data not shown). The LMβ1
andγ1 chains stained similarly for all theM12 LMcell lines; these chains
were located in both the cytoplasm and, to a lesser extent, the ECM
(Figure 4, A and B). The punctate staining pattern seen for the LMα4
and β2 chains in the matrix of the M12mac25 cells was even more pro-
nounced for the LMβ1 and γ1 matrix staining (Figure 4B), indicating
that these LM chains are deposited in a different manner than LM332
in these prostate cancer cells.
Altered expression of one ECM protein is often associated with
changes in other ECM proteins. Expression of fibronectin (FN), a fi-
brillar ECM protein, has been shown to alter during senescence, aging,
and cancer progression [29,32–34]. We found that the cell popula-
tions overexpressing the LMβ2 chain and displaying an elongated
morphology had increased amounts of fibrillar staining for FN com-
pared to theM12pc andM12α4 cells (Figure 4A). Staining of FN after
removal of the cells yielded a pronounced punctate staining pattern for
all the cells (Figure 4B).
Positive cytoplasmic staining of the various LMs occurred equally
well in both cuboidal and elongated cells; however, the amount of
three-dimensional matrix staining present correlated with the pre-
dominance of an elongated morphology. The cell populations con-
taining the largest number of elongated cells were also the ones
overexpressing the LMβ2 chain, suggesting that the higher protein
levels of the LMβ2 chain seen in the M12β2 and the M12α4β2 cells
may lead to altered three-dimensional deposition of matrix proteins,
including LMs and fibronectin.
Figure 2. Relative mRNA and protein levels of LM chains in the var-
ious M12 LM cells compared to levels in the M12 control cells. (A)
Laminin chain cycle numbers were normalized against GAPDH cycle
numbers (ΔC t). M12 normalized cycle numbers were subtracted
from the M12 LM cells (M12α4, M12α4β2, and M12β2) and
M12mac25 cell numbers to yieldΔΔC t values. The following formula
was used to derive relative quantitation values: RQ = 2 −ΔΔC t. Pri-
mary prostate epithelial cell levels are included to show relative phys-
iological levels of the LM α4 and β2 chains in primary prostate cells
compared to the transfected levels in the various M12 LM cells.
mRNA levels of the introduced laminin chains were significantly
higher for the M12 LM cells compared to the control M12 cell (P <
.0001). As with the M12 control cells, LM332 levels in the M12 LM
cells remained significantly lower than in thePECs (P< .001; data not
shown). (B) Western immunoblots for various LM chains. Either
whole cell lysates or concentrated conditioned media were run on
reducing SDS-PAGE gels. Heart, which expresses very high levels
of the LMα4 chain, was used as a positive control. Murine heart
was homogenized and lysed with the same lysis buffer as the M12
LM cells.
Figure 3. Morphology of transfected cells. M12α4 cells were similar in appearance to the M12 control cells. The M12β2 and M12α4β2
cells were a mix of cuboidal and elongated cells.
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Association of the LMβ2 Chain with LM332
Dual staining with the LMβ2 chain antibody and LM332 anti-
bodies demonstrated colocalization of these LM chains in the three-
dimensional fibrillar matrix as well as in the monolayer matrix
(Figure 5A). Likewise, immunoprecipitation of conditioned culture
medium showed association of the LMα3 chain with the β3 and β2
chains in cells overexpressing the LMβ2 chain; M12mac25 cells were
the exception because they produce very little of the LMα3 chain
but do express the LMβ2 chain (Figure 5B). Immunoprecipitation
with the LMγ2 chain also demonstrated an association with the
LMβ2 chain (Figure 5C ).
In Vitro Cellular Proliferation and Migration
To determine whether alterations in LMs affected proliferation, we
performed MTS assays. Five days after plating, M12β2 cells had the
highest proliferation rates followed by M12α4, M12α4β2, and
M12mac25 cells (Figure 6A). Next, we used wounding assays to assess
if altered LM production influenced cell migration. After wounding,
Figure 4. Immunofluorescent staining of various LM chains and fibronectin in the M12 LM cells. (A) Cells were fixed and stained for
various LM chains or fibronectin. All three LM332 chains stained similarly; LMγ2 chain staining is shown. (B) Staining of matrix after cells
were removed with 0.5% Triton X and 20 mM ammonium acetate. Removal of cells leaves a monolayer matrix and occasionally a three-
dimensional matrix, as was the case for the M12α4β2 cells. Removal of cells provided a clearer picture as to what LM chains were being
deposited in the ECM. Note the punctate staining pattern of fibronectin is similar to the pattern for the LMβ1γ1 and β2 matrix staining.
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cells redeposit matrix on which they migrate. All of the cells, except
M12mac25, deposit similar amounts of LM332 but differ in their
production of the LMα4 and β2 chains. Cells were wounded and then
exposed to RPMI medium minus growth factors and serum. Wound
closure was measured at early time points, such as 9 hours, which were
representative of migration rather than proliferation. The M12α4 and
M12β2 cells demonstrated a trend toward increased migration com-
pared to theM12pc cells; further, these cells had significantly increased
migration compared to the M12α4β2 and M12mac25 cells (P < .05;
Figure 6B). After 24 hours, all the M12 LM cells had piled up along
the original wound, whereas the M12pc cells had simply closed the
gap, and the M12mac25 cells had failed to migrate into the wound
(Figure 6C ). Because both the M12α4β2 and M12mac25 cells prolif-
erate poorly, these results suggest that the wound closure and the piling
up of cells in the M12α4β2 cultures were caused by the increased mi-
gration of these cells.
In Vivo Tumorigenicity
To examine in vivo tumorigenicity of the LM-overexpressing cells,
we injected 106 cells subcutaneously from each cell line into groups
of 10 male athymic nude mice and monitored tumor growth during
a period of 6 weeks. By 6 weeks, 100% of the M12β2, 90% of the
M12α4, and 70% of the M12α4β2 mice had tumors. In comparison,
100% of the mice injected with M12pc control cells had tumors and
none of the mice injected withM12mac25 had tumors. After 6 weeks,
the average tumor volume was significantly higher (P < .05) for the
M12β2 group compared to the M12α4β2 group (Figure 7). Whereas
the tumor volumes of the other groups were not significantly differ-
ent, the trend in tumor volume mirrored the trends seen for in vitro
proliferation and migration.
To determine whether LM overexpression was maintained in the tu-
mors, we digested a portion of each tumor with collagenase. Antibiotic-
resistant cells were regrown in tissue culture, and total RNA, whole cell
Figure 5. Colocalization of LMβ2 chainwith LM332 chains. (A) Dual staining ofmatrix revealed colocalization of the LMβ2 chainwith chains
found in LM332 in both the three-dimensional matrix and the matrix monolayer. (B and C) Immunoprecipitations (IPs) using the LMα3 and
LMγ2 antibodies followed by blotting with the LM β2 chain antibody demonstrated the presence of this chain in both LMα3 and LMγ2 IPs.
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lysates, and conditioned media were all collected and analyzed for LM
expression. mRNA levels for the LMα4 and β2 chains decreased signifi-
cantly (P < .05) in the tumors compared to preinjection levels; however,
the mRNA levels remained significantly higher than the LMα4 and β2
chain levels seen in theM12pc cells (P < .0001) andM12pc tumors (P <
.0001; Figure 8A). Western immunoblots demonstrated maintenance
of increased protein levels of the introduced LM chains (Figure 8B).
In various cancers, alterations in LMs have been associated with
changes in expression of other matrix proteins and angiogenesis
[22]. We examined the tumors for overall matrix composition; histo-
logic comparison of tumors demonstrated significantly more collagen
deposition in the matrix for the M12 LM-overexpressing lines com-
pared to the M12pc tumors (P < .05; Figure 9). Because alterations
in both collagen and LM expression, especially an increase in LM411
(α4β1γ1), occur during tumor angiogenesis, we stained tumors
against MECA. Because M12 LM cells are human, the MECA stain-
ing detects the host-derived tumor blood vessels. M12α4 tumors had
the highest staining intensity for MECA followed by the M12β2,
M12α4β2, and M12pc tumors (Figure 10B).
Discussion
Laminins are expressed in both normal and malignant prostate tis-
sue, but different isoforms predominate in each case. In nonmalignant
prostate ECM, LM332 is predominant [26,28,35]; the high mRNA
and protein levels of the LM α3, β3, and γ2 chains observed in the
PECs are consistent with previous data. LM332 has been shown to
be necessary for epithelial cell polarization during development of a
normal basal epithelial cell layer [36,37]. Without LM332, the basal
cell layer fails to develop, and the epithelial cell loses the cell-cell con-
tact protein E-cadherin, as well as other structurally significant mole-
cules, and is prone to phenotypic deregulation and transformation
[26]. LM332 is lost in progression to prostate cancer, and further
alterations, including cleavage of the α3 and β3 chains, occur as the
cancer becomes invasive or metastatic; these alterations and the loss of
normal LM332 may contribute to formation of a structurally weaker
ECM more conducive to metastases [26,28,38]. The mechanisms re-
sponsible for loss of LM332 are not well understood, although aberrant
methylation of promoter regions could lead to silencing of LM332
genes [39]. Various prostate cancer cell lines, including the LNCaP
line, have already been shown to mirror the in vivo loss of LM332
[40]; we demonstrate here that another prostate cancer cell line, M12,
has significantly decreased its production of LM332.
We found that nonsenescent PECs expressed abundant levels of
the LMβ2 chain but did not express the LMα4 chain. Our senescent
M12mac25 cells showed partially restored LMβ2 chain mRNA and
protein levels compared to PECs and demonstrated increased levels
of LMα4 chain mRNA and protein compared to both PECs and
M12 cells. Other laboratories have reported an increase in the
LMα4 chain transcript in senescent primary prostate fibroblasts [6]
and senescent prostate epithelial cells [6,41]. Our results suggest that
prostate cancer cells induced to undergo senescence alter their LM
production as well.
Figure 6. In vitro cellular proliferation and migration of the M12 LM cells compared to the M12 control cells. (A) Cellular proliferation was
measured with the MTS assay, which correlated to cell number. *P < .01, **P < .001 compared to M12β2 cells. (B) To determine
whether alterations to LM chain expression modulated the ability of the cells to migrate, we performed in vitro wounding assays as
described in the Methods section. The greatest differences in migration were seen at 9 hours after wounding. (C) Twenty-four hours
after wounding, all the cells except for the M12mac25 line had closed the wound. M12 LM cells piled up along the wound site, whereas
the site of the original wound could not be detected in the M12 control cells.
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Several studies have shown that LM expression is altered during
tumor progression [22,26]. In glial tumors, abnormalities in matrix
production develop in glial cells, adjacent stroma, and endothelial
cells. As in prostate cancer, there is loss of LM332 to a degree de-
pending on the depth within the tumor and the grade of tumor
[25,42,43]. Gliomas also exhibit elevated levels of the LMα4 chain,
and during glioblastoma progression, endothelial cells cease synthesis
of LM421 (α4β2γ1) in favor of LM411 [25,42]. This conversion
can be induced by coculture of glioblastoma cells and endothelial
cells, and the malignant phenotype can be reversed by reexpression
of LM421 [43]. A similar effect may occur in the prostate where
senescent stromal cells have been postulated to influence the cancer
phenotype of prostate epithelium. Prostate cancer cells can some-
times integrate with tumor vessels and coexpress vascular antigens,
a phenomenon termed vasculogenic mimicry, which facilitates tumor
progression [44,45]. These observations suggest that selective expres-
sion of LM411 and 421 influences the proliferative or differentiated
phenotype and that aberrant expression of LM411 by senescent or
tumor cells can influence the angiogenic potential of adjacent endo-
thelial cells, which in turn facilitates tumor growth and metastasis.
Because LMs are known ligands for various cell surface receptors,
they are important biologically as mediators of cellular behaviors such
as proliferation, migration, and tumorigenicity. However, there is a
paucity of studies examining the direct role of LMs in prostate cancer
or senescence. Most studies on alterations in LM composition during
cancer progression focus on immunohistochemical changes in pros-
tate tissue samples [26,28,35]. The few functional studies on LMs
have concentrated on LM511 (α5β1γ1) and its cleavage products
and on their role in increased migration of prostate cancer cells
[46,47]. One study has been reported in which the LMβ3 chain
was transfected into the LNCaP prostate cancer cell line. Although
punctate deposition of the LMβ3 chain occurred along cell surfaces,
the authors were unable to detect either secretion or the classic mono-
layer deposition of the LM332 trimer into the matrix. However, the
reexpression of the LMβ3 chain still resulted in increased tumor for-
mation in vivo and altered expression of genes involved in various
growth signaling pathways on cDNA arrays [40], which suggests
that individual LM chains may have unexplored biological functions.
Our LM transfected cells, however, secreted and deposited the in-
troduced LM chains. Furthermore, we found that introduction of
the LMβ2 chain was associated with an alteration in deposition of
the endogenous LM332. Compared to the M12pc empty vector cells
and the M12α4 cells, staining against the LM332 chains in the
M12β2 and M12α4β2 cells showed both a classic monolayer depo-
sition and a fibrillar three-dimensional staining pattern. Whereas
primary epithelial cells normally deposit LM332 in a monolayer
Figure 7. In vivo tumorigenicity of the various M12 LM cells compared to M12 control cells. Groups of 10 male athymic nude mice were
subcutaneously injected with 1 × 106 cells and followed for 6 weeks. Tumor volume was calculated using the following formula: (l ×
w2)/2. Mice injected with M12β2 cells displayed the greatest tumor growth, whereas mice injected with M12α4β2 displayed the slowest
tumor growth. *P < .01 compared to M12β2 tumors. M12mac25 cells did not form tumors in vivo.
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in vitro, three-dimensional deposition of LM332 can occur in vitro
when these cells are cocultured with fibroblasts that secrete large
amounts of fibronectin. The epithelial cells deposit LM332 along
the fibronectin fibers, separating themselves from the fibroblasts in
discrete “nests” [31]. Immunohistochemical studies on various can-
cers, including prostate, demonstrate that primary tumors often form
their own basement membrane, separating themselves from the sur-
rounding stroma [4,22,26,48].
Our observation that the introduction of the LMα4 and β2 chains
altered the deposition of matrix proteins prompted our exploration of
the effects of altered LM expression on cell behavior. We found that
in vitro proliferation and migration were, in general, enhanced by in-
creased expression of either the LMα4 or β2 chains but decreased if
both chains were highly expressed. In vivo tumor formation followed
the same trend. Mouse endothelial cell antigen staining of these tu-
mors demonstrated increased tumor vasculature in the M12α4 tu-
mors compared to the M12β2 and M12α4β2 tumors. These results
agree with immunohistochemical studies on breast cancer and glio-
blastoma samples, which demonstrated that high levels of LMα4
protein expression were associated with tumor vasculature and in-
creased tumorigenicity, whereas expression of both the LMα4 and
β2 chains was associated with decreased tumorigenicity and normal
vasculature [24,25,49].
Only a few studies examining the LMβ2 chain in cancer have been
reported. Immunohistochemical studies on LMs suggest increased
staining for the LMβ2 chain in prostate cancer tissue samples com-
pared to normal prostate [48] and increased LMβ2 staining in ovarian
tumor basement membranes, especially in lower-grade cancers
Figure 8. Relative LMα4 and β2 expression in in vivo tumors. A portion of each tumor was digested with collagenase, then the antibiotic-
resistant cells were regrown in vitro and total RNA and whole cell lysates were collected. (A) RNA was converted to cDNA, and real-time
PCR was run using primers against the LMα4 and β2 chains. Whereas the levels of introduced LM chain mRNA decreased compared to
preinjected levels, the tumor levels remained significantly higher than the LMα4 and β2 chain levels seen in the M12 control cells (P <
.0001) and M12 tumors (P < .0001). (B) Western immunoblots against the LMβ2 and α4 chains. Lysates were run on reducing SDS-
PAGE gels. As shown here, the introduced LM chains were still highly expressed by the tumor cells.
Figure 9. Collagen staining of in vivo tumors. Masson’s Trichrome
staining, which stains primarily the collagen component of the
ECM, was performed on fixed tumor sections. Staining intensity
was scored for each tumor, and the average intensity was calcu-
lated per group. The amount of collagen present was significantly
higher for theM12α4 tumors (P< .05) compared to theM12 tumors.
Neoplasia Vol. 10, No. 12, 2008 LM Changes Regulate Prostate Cancer Progression Sprenger et al. 1359
[50,51]. In addition, there is one report in the literature regarding hy-
povascular, mega-adenomas in pituitary cancers. Using an in vitro
model of hypoxia in pituitary tumors, Bao et al. [52] demonstrated
a correlation between increased LMβ2 chain protein (but not the
other LM chains) and decreased oxygen concentration. Further, im-
munohistochemical analysis of pituitary adenoma sections showed a
significant correlation between staining intensity for the LMβ2 chain
and increased size of the tumor. It would be of interest to see what role
hypoxia plays in the relatively hypovascular M12β2 tumors.
The previously mentioned studies, however, did not determine
the identity of the mature β2-containing LM trimer involved in these
ECM-rich cancers. We have presented data suggesting that the LMβ2
chain is associated with the LMα3 chain in the M12 prostate cells
overexpressing the LMβ2 chain. Whether this is a direct association re-
sulting in a LM321 trimer or simply a β2-containing LM complexing
with LM332 is not known because immunoprecipitations with both
the LMα3 and γ2 chains pulled down the LMβ2 chain, and immuno-
fluorescent staining demonstrated costaining of the LMβ2 and LMβ3
chains as well. Champliaud et al. [53] suggest that the LMβ2 chain
can directly bind the LMα3 chain to form a LM321 trimer. Further,
they argue that LM332, LM321, and LM311 form a complex in normal
epithelial basement membranes. Therefore, a complex of LM332, 311,
and 321 is a possibility in the LMβ2-overexpressing cells, although the
formation of such a complex has not been examined in cancer cells.
Expression of the LMβ2 chain alone has a tumor promoting func-
tion as opposed to the tumor suppressive role seen with high protein
levels of the LMα4 and β2 chains together. The mechanisms be-
hind this dichotomy in function for the LM β2 chain remain to be
elucidated, but this observation supports the idea that both tumor-
promoting and tumor-inhibiting factors secreted by senescent cells
combine or interact to influence cellular behavior. Identification of
the factors secreted by senescent cancer cells and their effects on the
regression or progression of the remaining tumor will have important
implications for future cancer modalities.
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